Loading provider…
Loading provider…
Hematology & Oncology Physician in Wheeling, WV
NPI: 1154598498Primary Practice Location
WHEELING HOSPITAL, INC
1 Medical Park, Wheeling, WV
Primary Employer
Wheeling Hospital Inc
wvumedicine.org
HQ Phone
Get D.O. Bhavana's Phone Numberphone_androidMobile
Get D.O. Bhavana's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
WV State Medical License

OH State License
2007 - 2027

WV State License
2021 - 2027

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
University of Maryland
Fellowship • Hematology and Medical Oncology
2010 - 2013
Cleveland Clinic Foundation
Residency • Internal Medicine
2007 - 2010
Pcom
Medical School
Until 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 132 | 179 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 76 | 142 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 39 | 39 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 29 | 29 |
| 5 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 24 |
Authors: Sarah Wall, John Byrd, James Blachly, Bradley Blaser, Sumithira Vasu, Karilyn Larkin, Nicole Grieselhuber, Alice Mims, Tzu-Fei Wang, Alison Walker
Journal: Int J Hematol Oncol
Publication Date: 2020-09-04
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Authors: John Byrd, James Blachly, Michael Grever, Sumithira Vasu, Karilyn Larkin, Guido Marcucci, Shylaja Mani, William Blum, Alice Mims, Alison Walker
Publication Date: 2020-06-01
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Blinatumomab, BIOLOGICAL: Inotuzumab Ozogamicin
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Biospecimen Collection, DRUG: Prednisone, DRUG: Vincristine Sulfate, DRUG: Methotrexate, PROCEDURE: Computed Tomography, PROCEDURE: X-Ray Imaging, DRUG: Vincristine, DRUG: Dasatinib, BIOLOGICAL: Blinatumomab, DRUG: Mercaptopurine, PROCEDURE: Biopsy Procedure, PROCEDURE: Echocardiography Test, PROCEDURE: Bone Marrow Aspiration and Biopsy, PROCEDURE: Lumbar Puncture, DRUG: Methotrexate Sodium
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, DRUG: Sapanisertib